logo
FUJIFILM Sonosite Redefines Superficial Imaging with the New UHF46-20 Transducer, the World's First 46MHz Ultra High Frequency Transducer for Point-of-Care Ultrasound

FUJIFILM Sonosite Redefines Superficial Imaging with the New UHF46-20 Transducer, the World's First 46MHz Ultra High Frequency Transducer for Point-of-Care Ultrasound

Business Wire5 days ago
BOTHELL, Wash.--(BUSINESS WIRE)-- FUJIFILM Sonosite, Inc., the world leader in point-of-care ultrasound (POCUS) solutions, today announced a revolutionary advancement in point-of-care ultrasound imaging with the introduction of their UHF46-20 Transducer. This groundbreaking transducer is the first and only 46MHz Ultra-High Frequency (UHF) transducer available today in the point-of-care ultrasound market 1, setting a new standard for superficial image clarity and detail.
With a minimum scan depth of 4mm, the UHF46-20 Transducer will enable clinicians to clearly visualize the first one to two centimeters beneath the skin and identify structures smaller than 1mm, such as superficial nerves and vessels, with high-quality resolution. Built upon the advanced Ultra High Frequency technology from FUJIFILM VisualSonics, and available exclusively on the FUJIFILM Sonosite LX POCUS system, this innovative technology provides the best superficial imaging 2,3,4 available on any point-of-care ultrasound system 1.
'At FUJIFILM Sonosite, we are driven by a commitment to help solve real-world challenges clinicians and providers face. The UHF46-20 transducer, when paired with the Sonosite LX system, enables the largest frequency range of any point-of-care ultrasound system on the market today - addressing a longstanding challenge that current clinical ultrasound systems have been unable to overcome,' said Richard Fabian, president and chief executive officer of FUJIFILM Sonosite, Inc. 'We're proud to bring to market the UHF46-20 Transducer as the first and only 46MHz UHF transducer in POCUS to provide clinicians with an unparalleled tool that may help them enhance diagnostic confidence and procedural accuracy.'
The combination of the new transducer and the Sonosite LX offers clinicians a versatile solution for a wide spectrum of imaging needs, spanning from deep abdominal scans to ultra-high resolution superficial assessments. The UHF46-20 Transducer holds promise for improving outcomes across a range of sensitive applications including Neonatal Intensive Care Unit (NICU) and Rheumatology. In the NICU, its superior resolution may help clinicians see superficial submillimeter anatomy that conventional ultrasound may not capture. 6,11 The use of UHF ultrasound may aid clinicians in improving procedural quality by allowing for better visualization of tiny anatomy that may help to improve first attempt success rates. 4,8,9,10 In Rheumatology, UHF's advanced superficial imaging may aid in the visualization of subclinical synovitis, erosions, crystal deposits, and inflammation, all of which are beneficial in the early diagnosis and intervention of chronic conditions. 2,3,7
To learn more about the UHF46-20 Transducer, visit the product page at https://www.sonosite.com/products/ultrasound-transducers/sonosite-uhf-46-20.
About FUJIFILM
FUJIFILM Sonosite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra-high frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by a global distribution network in over 100 countries. Sonosite's portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, please visit www.sonosite.com.
FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen. For more information, please visit: https://holdings.fujifilm.com/en.
References
Internal Fujifilm research as of April 2025.
Albano, D., Aringhieri, G., Messina, C., De Flaviis, L., & Sconfienza, L. M. (2020). High-Frequency and Ultra-High Frequency Ultrasound: Musculoskeletal Imaging up to 70 MHz. Seminars in musculoskeletal radiology, 24 (2), 125–134. https://doi.org/10.1055/s-0039-3401042
Russo, A.; Reginelli, A.; Lacasella, G.V.; Grassi, E.; Karaboue, M.A.A.; Quarto, T.; Busetto, G.M.; Aliprandi, A.; Grassi, R.; Berritto, D. Clinical Application of Ultra-HighFrequency Ultrasound. J. Pers. Med. 2022, 12, 1733. https://doi.org/ 10.3390/jpm12101733
Ait Ichou, J., Gauvin, S., & Faingold, R. (2021). Ultra-high-frequency ultrasound of superficial and musculoskeletal structures in the pediatric population. Pediatric radiology, 51 (9), 1748–1757. https://doi.org/10.1007/s00247-021-04978-0
Hayashi, A., Giacalone, G., Yamamoto, T., Belva, F., Visconti, G., Hayashi, N., Handa, M., Yoshimatsu, H., & Salgarello, M. (2019). Ultra High-frequency Ultrasonographic Imaging with 70 MHz Scanner for Visualization of the Lymphatic Vessels. Plastic and reconstructive surgery. Global open, 7 (1), e2086. https://doi.org/10.1097/GOX.0000000000002086
Latham, G. J., Veneracion, M. L., Joffe, D. C., Bosenberg, A. T., Flack, S. H., & Low, D. K. (2013). High-frequency micro-ultrasound for vascular access in young children--a feasibility study by the High-frequency UltraSound in Kids studY (HUSKY) group. Paediatric anaesthesia, 23 (6), 529–535. https://doi.org/10.1111/pan.12131
Viviano, S. L., Chandler, L. K., & Keith, J. D. (2018). Ultrahigh Frequency Ultrasound Imaging of the Hand: A New Diagnostic Tool for Hand Surgery. Hand (New York, N.Y.), 13(6), 720–725. https://doi.org/10.1177/1558944717731856
Jacobsen RB, Hebelka H, Gatzinsky V, Elfvin A, Dangardt F. Ultra-high-frequency ultrasound (48–70 MHz) is a promising tool for improved gastrointestinal diagnostics in infants. Acta Paediatr. 2024; 113: 2304–2311. https://doi.org/10.1111/apa.17342
Brusciano, V., & Lecce, M. (2024). Advantages of the use of ultrasound in newborn vascular access: a systematic review. Journal of ultrasound, 27 (2), 203–207. https://doi.org/10.1007/s40477-023-00832-1
Currie M, Vashisht R, Elkin D, et al. Ultrasound Intravascular Access. [Updated 2024 Jul 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448093/
Salvia, G.; Zerbinati, N.; Manzo Margiotta, F.; Michelucci, A.; Granieri, G.; Fidanzi, C.; Morganti, R.; Romanelli, M.; Dini, V. Ultra-High-Frequency Ultrasound as an Innovative Imaging Evaluation of Hyaluronic Acid Filler in Nasolabial Folds. Diagnostics 2023, 13, 2761. https://doi.org/10.3390/ diagnostics13172761
Hawez, T., Evertsson, M., Erlöv, T. et al. The use of ultra-high frequency ultrasound in identifying aganglionosis in Hirschsprung's disease. Sci Rep 15, 15124 (2025). https://doi.org/10.1038/s41598-025-99897-7
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Thermon(R) Introduces Poseidon(TM) and Pontus(TM) Liquid Load Banks: Revolutionizing Data Center Commissioning and Validation
Thermon(R) Introduces Poseidon(TM) and Pontus(TM) Liquid Load Banks: Revolutionizing Data Center Commissioning and Validation

USA Today

time13 minutes ago

  • USA Today

Thermon(R) Introduces Poseidon(TM) and Pontus(TM) Liquid Load Banks: Revolutionizing Data Center Commissioning and Validation

AUSTIN, TX / ACCESS Newswire / July 29, 2025 / Thermon Group Holdings, Inc. (NYSE:THR) ('Thermon'), a global leader in thermal management, power distribution, and environmental controls, today announced its universal availability of their new Poseidon™ Liquid Load Bank (for US markets) and Pontus™ Liquid Load Bank (for non-US markets). These advanced systems are designed to accurately simulate real-world thermal and electrical demand, providing mission critical component test validation for data centers and other High Performance Computing (HPC) environments. The new liquid load banks offer a built-for-purpose solution for the rigorous demands of data center commissioning and start up. They serve as essential test validation systems for critical HPC data center infrastructure, like Coolant Distribution Units, Uninterruptible Power Supplies and back-up power generators. Key features and benefits of the Poseidon and Pontus Load Banks include: A built-for-purpose liquid-cooled load bank targeting the data center commissioning and start-up market, including Integrated Systems Testing. Industry-leading performance, sizing, and weight, contributing to the lower total cost of ownership. Engineered for data center testing applications – with integrated modern controls and monitoring in a standardized package for quick delivery. Simple, easy controls and a comprehensive audible alarm system to indicate high temperature, low flow, and low water conditions. Modular design with the ability to connect over 100 units in series to test the increasing IT loads in the industry. Custom designed and optimized by process heating/heat transfer experts, but standardized for quicker lead times and more value, the Poseidon and Pontus Load Banks boast a robust capacity rating up to 600kW within a compact design. Built for rapid deployment, these lightweight systems feature a mobile, space-saving design, allowing for quick and efficient testing in different locations within modular, mobile HPC and other data center environments. Poseidon and Pontus load banks provide real-time oversight of the dynamic thermal performance and electrical demands crucial for a modern data center in the rapidly expanding age of artificial intelligence (AI). 'The launch of the Poseidon and Pontus Liquid Load Banks marks a significant milestone for Thermon – greatly expanding our opportunity within the rapidly growing data center market.' said Bruce Thames, President & CEO of Thermon. 'As data centers evolve to meet the intense demands of AI and HPC, the need for precise, reliable, and efficient validation tools is paramount. Our new liquid load banks deliver unparalleled performance, mobility, and ease of use, reinforcing Thermon's commitment to providing innovative solutions that empower our customers to build and operate the most robust and efficient critical infrastructure.' The new liquid load banks are available globally and are certified to local requirements along with the following applicable standards: UL, CSA, CE, ASME, ANSI, NEMA, PED and NEC, ensuring compliance and reliability across diverse markets. For more information on the Poseidon and Pontus load banks, click here. Through its global network, Thermon provides safe, reliable and mission critical industrial process heating solutions. Thermon specializes in providing complete flow assurance, process heating, temperature maintenance, freeze protection and environmental monitoring solutions. Thermon is headquartered in Austin, Texas. For more information, please visit CONTACT: Michelle Saab, Senior Manager, Global Marketing Phone: +1-512-560-5482 SOURCE: Thermon Group Holdings Inc. View the original press release on ACCESS Newswire

Children's of Alabama and University of Alabama at Birmingham Study Shows Association with a 30% Reduction in Mechanical Ventilation Using Etiometry's Clinical Intelligence Platform
Children's of Alabama and University of Alabama at Birmingham Study Shows Association with a 30% Reduction in Mechanical Ventilation Using Etiometry's Clinical Intelligence Platform

Yahoo

time35 minutes ago

  • Yahoo

Children's of Alabama and University of Alabama at Birmingham Study Shows Association with a 30% Reduction in Mechanical Ventilation Using Etiometry's Clinical Intelligence Platform

The study also observed a 20% decrease in overall hospital length of stay for post-surgical patients BOSTON, July 29, 2025--(BUSINESS WIRE)--A newly published study in the Journal of Pediatric Critical Care (JPCC) has demonstrated that integrating Etiometry's Clinical Intelligence Platform at the Children's Hospital of Alabama observed association with significantly improved patient outcomes in the pediatric cardiac intensive care unit (ICU). The study observed a 30% reduction in mechanical ventilation duration and a 20% decrease in overall hospital length of stay for post-surgical patients. The research, titled Automated Spontaneous Breathing Trial Performance Tool is Associated with Improved Outcomes Following Pediatric Cardiac Surgery: A Single-Center Retrospective Study from Alabama, USA, evaluated the implementation of an automated spontaneous breathing trial (SBT) performance tool from Etiometry's Clinical Intelligence Platform. This innovative approach leverages near real-time clinical and ventilator data to automate the hospital's Extubation Readiness Test (ERT) practices, driving more timely initiation and more consistent adherence to the practices. This results in both reduced time on mechanical ventilation and length of hospital stay. The study's findings indicate that the deployment of Etiometry's SBT tool was associated with a significant reduction in postoperative total ventilation time (TOV) and length of stay (LOS). Specifically, the incidence rate for postoperative TOV was 0.7 times lower post-implementation (P < 0.0001), and the postoperative LOS was reduced by 20% (0.81 times, P < 0.01). The single-center study's significant dataset of 787 pediatric patients makes the findings highly relevant for this patient population. "The observed reduction in the duration of mechanical ventilation in this study may be clinically meaningful," said Dr. Santiago Borasino, medical director of the cardiovascular intensive care unit at Children's of Alabama professor at the University of Alabama at Birmingham, and the study's principal investigator. "When we are able to reduce a patient's time on mechanical ventilation, we are also decreasing their risk of complications such as pneumonia and potentially helping them recover faster and shorten their stay in the ICU. These improved patient outcomes benefits translate to freeing up ICU resources and ultimately, cost savings for hospitals." The results of this study highlight the impact of integrating automated clinical intelligence tools into ICU workflows. By enabling proactive decision-making, Etiometry's platform empowers care teams to optimize mechanical ventilation strategies, reducing hospital stays and improving patient outcomes. To access the full study, visit: About Children's of Alabama Since 1911, Children's of Alabama has provided specialized medical care for ill and injured children, offering inpatient, outpatient and primary care throughout Central Alabama. Ranked among the best children's hospitals in the nation by U.S. News & World Report, Children's serves patients from every county in Alabama and nearly every state. Children's is a private, not-for-profit medical center that serves as the teaching hospital for the University of Alabama at Birmingham (UAB) pediatric medicine, surgery, psychiatry, research and residency programs. The medical staff consists of UAB faculty and Children's full-time physicians, as well as private practicing community physicians. About Etiometry Founded in 2010, Etiometry is a leader in clinical decision-support software designed to help clinicians in intensive care units make data-driven, proactive decisions. By leveraging advanced analytics and AI-powered insights, the company empowers care teams to detect subtle changes in patient conditions, prevent complications, and improve recovery times. Etiometry has received ten FDA clearances and is trusted by leading healthcare institutions worldwide, including top-ranked academic medical centers and pediatric hospitals. The company is committed to advancing patient safety, improving clinical efficiency, and lowering the cost of care through smarter data utilization. Etiometry's risk analytics support clinician review of physiologic trends and may aid in awareness of patient trajectory. The platform does not diagnose or treat. To learn more, visit View source version on Contacts Media Hyedi Nelson Bellmont PartnersHyedi@ 651-757-7054 Tachana Johnson Senior Media Relations CoordinatorChildren's of AlabamaOffice: 205-638-2947Media Relations On Call: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Super Micro (SMCI) Rallies 10.2% as US Freezes Export Curbs to China
Super Micro (SMCI) Rallies 10.2% as US Freezes Export Curbs to China

Yahoo

time42 minutes ago

  • Yahoo

Super Micro (SMCI) Rallies 10.2% as US Freezes Export Curbs to China

We recently published . Super Micro Computer, Inc. (NASDAQ:SMCI) is one of the best-performing stocks on Monday. Super Micro jumped for a fourth straight day on Monday, adding 10.24 percent to close at $60.05 apiece as investors cheered President Donald Trump's decision to freeze export restrictions on technology products to China as Washington and Beijing resume trade negotiations. The US and China will meet in Stockholm for a third round of trade talks on Monday, following previous meetings in Geneva and London. Known for its AI-focused server systems, Super Micro Computer, Inc. (NASDAQ:SMCI) is one of the companies benefiting from increased technology spending this year. Year-to-date, its stock has gone up by almost 100 percent as more companies globally build large artificial intelligence workloads. Copyright: wavebreakmediamicro / 123RF Stock Photo In other developments, Super Micro Computer, Inc. (NASDAQ:SMCI) is set to announce the results of its earnings performance for the fourth quarter of fiscal year 2025 after market close on August 5. An investor call will be held on the same day to elaborate on the results. While we acknowledge the potential of SMCI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store